On December 11, 2023, an injection pen of the weight loss drug of Elli Lily, Zapebound, Elli Lily’s weight loss drug is displayed in New York City.
Brendon McDermid | Roots
Ellie lily The pharmaceutical giant’s weight loss drug Jeepbounds and its diabetes treatment Mounaro are sueing four telehaalth companies selling the mixed versions of Mounaro, for the company’s latest efforts to crack down on the growing industry of copycat drugs.
In cases filed on Wednesday, Lily accused the sites – cobbler Health, Fella Health, Willow Health and Henry Meds – to cheat consumers about “unused, unpublished medicines” and to remove them from lily drugs.
Lily alleged that companies are claiming to offer personal options when they are actually crossing slightly different versions of lily drugs to skirt the FDA rules. Lily also claims that some sites are selling formulations of drugs that have not been studied, such as oral tablets and drops.
Mochi, Fella, Wilo and Henry Meds did not immediately respond to CNBC’s requests for comments.
Lily’s diabetes drugs went into low supply at the end of 2022, allowing pharmacies and outsourcing features to produce treatment, a practice called compounding. The weight loss drug of Novo Nordisk was also in low supply, which was opening the market to compound GLP-1s.
The business was bounced online, where people demanded versions of treatment if they could not get the brand name Or they could not be covered by insurance. The active ingredient in Munjaro and Zepbounds, the mass compounding of the tirzepatide, was about to stop last month when the food and the drug administration announced the lack of drugs.
Some pharmacies did so anyway, producing versions that are slightly different from the brand name, possibly keeping them out of the FDA crosshair. Earlier this month, Lily Lawsed on Two pharmacies alleged that they have marketed their products as individual versions of drugs that have been clinically tested and created using stringent safety standards.
One of the telehaalth platforms is now prosecuting, cobbler Health, has planned to continue selling mixed versions of Tirzepetide, making a condition that individual treatment offers will keep it out of legal trouble, cobbler’s CEO Myra Ahmed Told CNBC in March.
Asked if she feared legal action from Lily, Ahmed said that she was not worried about her prescriptions because “she has established patient-medical relations” and “The beauty of the drug is really that they get complete autonomy to decide what their best way to manage their patients.”
In her filing on Wednesday, Lily claimed that Ahmed is not a licensed physician and the cobbler and its “unlicensed owners are attached to the prescribed decisions” and as a result “illegal corporate exercises”, as a result.
Lily Fella makes a similar allegation against Health, accusing the company “corporate decision -making corporate decision making, such as when Fala replaced the patients with a tirzepetide formulation with additives.”
In all four cases, lily is trying to prevent site from selling marketing or selling tirazepatide. But it may take months for cases to make their way through courts, or even more time.
